B. Riley raised the firm's price target on Eton Pharmaceuticals to $31 from $26 and keeps a Buy rating on the shares. Following a strong Q4, Eton delivered enhanced revenue visibility with FY26 guidance above $110M and more than 30% adjusted EBITDA margin, alongside long-term targets of a $200M run-rate exiting 4Q27, 50% margins by 2028, and $500M revenue by 2030, reinforcing a multi-year growth trajectory, the analyst tells investors in a research note.
